Legal & General Group PLC Sc Pharmaceuticals Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Sc Pharmaceuticals Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,571 shares of SCPH stock, worth $25,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,571

Previous 3,861 18.39%

Holding current value

$25,917

Previous $14,000 78.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$3.86 - $5.84 $2,740 - $4,146	710 Added 18.39%	4,571 $25,000
Q2 2025 Aug 12, 2025	SELL	$2.02 - $4.27 $1,139 - $2,408	-564 Reduced 12.75%	3,861 $14,000
Q4 2024 Feb 13, 2025	BUY	$3.14 - $4.53 $4,414 - $6,369	1,406 Added 46.57%	4,425 $15,000
Q3 2024 Feb 28, 2025	SELL	$4.12 - $5.51 $5,792 - $7,747	-1,406 Reduced 31.77%	3,019 $13,000
Q1 2024 May 29, 2025	SELL	$4.86 - $6.39 $6,833 - $8,984	-1,406 Reduced 31.77%	3,019 $15,000

Q4 2023 May 29, 2025	SELL	$4.7 - $6.63 $6,608 - $9,321	-1,406 Reduced 31.77%	3,019 $18,000
Q3 2023 Nov 14, 2023	SELL	$7.0 - $9.82 $3,269 - $4,585	-467 Reduced 13.4%	3,019 $21,000
Q2 2023 Aug 14, 2023	BUY	$8.94 - $11.74 $31,164 - $40,925	3,486 New	3,486 $35,000
Q2 2021 Aug 12, 2021	SELL	$5.19 - $7.38 $4,292 - $6,103	-827 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$7.12 - $8.86 $370 - $460	-52 Reduced 5.92%	827 $6,000
Q2 2020 Aug 14, 2020	BUY	$7.01 - $10.96 $6,161 - $9,633	879 New	879 $6,000
Q3 2019 Nov 13, 2019	SELL	$3.24 - $7.35 $4,098 - $9,297	-1,265 Closed	0 $0
Q1 2018 May 17, 2018	BUY	$11.62 - $17.32 $14,699 - $21,909	1,265 New	1,265 $16,000

Others Institutions Holding SCPH

# of Institutions

116

Shares Held

38.3M

Call Options Held

835K

Put Options Held

173K

View Full List

About scPharmaceuticals Inc.

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $155M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

More about SCPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Sc Pharmaceuticals Inc. Transaction History